Inari Medical Stock Investor Sentiment
| NARI Stock | USD 51.03 0.20 0.39% |
Under 60% of all Inari Medical's traders are looking to take a long position. The analysis of overall sentiment of trading Inari Medical stock suggests that some investors are interested at this time. Inari Medical's investing sentiment shows overall attitude of investors towards Inari Medical.
Inari |
Inari Medical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Inari Medical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Inari Medical that are available to investors today. That information is available publicly through Inari media outlets and privately through word of mouth or via Inari internal channels. However, regardless of the origin, that massive amount of Inari data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inari Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inari Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inari Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inari Medical alpha.
Inari Medical Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 3000 shares by Hill, Mitch C. of Inari Medical at 0.457 subject to Rule 16b-3 | 09/12/2024 |
2 | Disposition of 7386 shares by William Hoffman of Inari Medical at 46.27 subject to Rule 16b-3 | 09/16/2024 |
3 | Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. and Encourages Investors to Contact the Firm | 09/17/2024 |
4 | Disposition of 20000 shares by William Hoffman of Inari Medical at 50.15 subject to Rule 16b-3 | 09/25/2024 |
5 | Disposition of 458 shares by Hill, Mitch C. of Inari Medical at 40.63 subject to Rule 16b-3 | 10/01/2024 |
6 | Disposition of 632 shares by Tu Thomas of Inari Medical at 40.63 subject to Rule 16b-3 | 10/03/2024 |
7 | Disposition of 12196 shares by William Hoffman of Inari Medical at 45.57 subject to Rule 16b-3 | 10/16/2024 |
8 | Inari Medical Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 10/30/2024 |
9 | Inari Medical CEO Andrew Hykes sells 150,000 in stock | 10/31/2024 |
10 | Inari Medical, Inc. Director William Hoffman Sells 40,000 Shares | 11/01/2024 |
11 | Is Inari Medical Trading at an Attractive Valuation | 11/07/2024 |
12 | Insider Trading | 11/11/2024 |
13 | Analysts Recent Ratings Updates for Inari Medical | 11/13/2024 |
14 | Disposition of 9750 shares by William Hoffman of Inari Medical at 51.16 subject to Rule 16b-3 | 11/18/2024 |
15 | Disposition of 3000 shares by Andrew Hykes of Inari Medical at 50.83 subject to Rule 16b-3 | 11/20/2024 |
16 | Insider Selling Inari Medical, Inc. Director Sells 60,000 Shares of Stock | 11/21/2024 |
Complementary Tools for Inari Stock analysis
When running Inari Medical's price analysis, check to measure Inari Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inari Medical is operating at the current time. Most of Inari Medical's value examination focuses on studying past and present price action to predict the probability of Inari Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inari Medical's price. Additionally, you may evaluate how the addition of Inari Medical to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |